Alemtuzumab: A Review of Its Use in Patients with Relapsing Multiple Sclerosis-Reference-Cited by-同舟云学术

Alemtuzumab: A Review of Its Use in Patients with Relapsing Multiple Sclerosis

Published:2014-03 Issue:4 Volume:74 Page:489-504
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Garnock-Jones Karly P.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-014-0195-7.pdf

Reference43 articles.

1. World Health Organisation and Multiple Sclerosis International Federation. Atlas: multiple sclerosis resources in the world 2008. 2008. http://www.who.int/mental_health/neurology/Atlas_MS_WEB.pdf?ua=1 . Accessed 29 Jan 2014.

2. Brown JWL, Coles AJ. Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis. Drug Des Devel Ther. 2013;7:131–8.

3. National Institute for Health and Care Excellence. Multiple sclerosis: management of multiple sclerosis in primary and secondary care. NICE guideline. 2003. http://www.nice.org.uk/nicemedia/live/10930/29199/29199.pdf . Accessed 4 Nov 2013.

4. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169–78.

5. Williams T, Coles A, Azzopardi L. The outlook for alemtuzumab in multiple sclerosis. BioDrugs. 2013;27(3):181–9.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging trends and therapeutic applications of monoclonal antibodies;Gene;2024-10

2. Customer-centric product presentations for monoclonal antibodies;AAPS Open;2023-01-23

3. Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis;Drugs;2020-12-24

4. Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder;Journal of Clinical Neurology;2020

5. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date;Expert Opinion on Biological Therapy;2019-05-24